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Abstract: Glycolytic isozymes that are restricted to the male germline are potential targets for the development of re-
versible, non-hormonal male contraceptives. GAPDHS, the sperm-specific isoform of glyceraldehyde-3-phosphate dehy-
drogenase, is an essential enzyme for glycolysis making it an attractive target for rational drug design. Toward this goal, 
we have optimized and validated a high-throughput spectrophotometric assay for GAPDHS in 384-well format. The assay 
was stable over time and tolerant to DMSO. Whole plate validation experiments yielded Z’ values >0.8 indicating a robust 
assay for HTS. Two compounds were identified and confirmed from a test screen of the Prestwick collection. This assay 
was used to screen a diverse chemical library and identified fourteen small molecules that modulated the activity of re-
combinant purified GAPDHS with confirmed IC50 values ranging from 1.8 to 42 M. These compounds may provide use-
ful scaffolds as molecular tools to probe the role of GAPDHS in sperm motility and long term to develop potent and selec-
tive GAPDHS inhibitors leading to novel contraceptive agents.  
Keywords: Glycolysis, GAPDHS, high throughput screening, sperm, contraceptive. 
INTRODUCTION 
  Sperm-selective targets are being investigated to develop 
novel, reversible small molecule contraceptives. These in-
clude distinct isozymes in the glycolytic pathway [1-5], such 
as glyceraldehyde-3-phosphate dehydrogenase S (GAPDHS) 
[6, 7]. GAPDHS is ~70% identical to its somatic GAPDH 
isozyme, with amino acid differences distributed along the 
length of the protein [5, 8, 9]. The most distinctive structural 
feature of the sperm isozyme is a proline-rich N-terminal 
region that has no homology to somatic GAPDH enzymes 
from widely divergent species. Expression of GAPDHS is 
restricted to the male germline, offering the potential for 
contraception by selective inhibition of sperm metabolism 
without blocking glycolysis in other tissues. Gene targeting 
studies determined that mice lacking GAPDHS are infertile 
and produce sperm with very low ATP levels and no pro-
gressive motility [10]. These studies demonstrate the impor-
tance of glycolysis for sperm energy production and also 
provide evidence that inhibition of GAPDHS should not im-
pair testicular function, since sperm production is unaffected 
in mice lacking this enzyme [10].  
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 Early  studies  identified  -chlorohydrin and related   
derivatives as potential male contraceptives with reversible 
effects on fertility at low doses (reviewed in [11, 12]). Nu-
merous reports detailed the inhibitory effects of -
chlorohydrin on GAPDHS activity, its ability to impair 
sperm motility and fertility and its selectivity versus the so-
matic GAPDH. However, side effects were observed in vivo 
[11-13]. More recently, structure-based drug design ap-
proaches have been applied to GAPDHS (from rat) to iden-
tify novel leads for male contraceptive development [7]. Few 
differences were observed between the active sites of human 
somatic GAPDH and sperm-specific GAPDHS, although 
differences elsewhere on the protein were noted that might 
be targetable for selective inhibitors of GAPDHS [7]. 
   Drug targeting of GAPDH enzymes is not restricted to 
contraceptive studies. Compounds to inhibit pro-apoptotic 
activity of human GAPDH are also being investigated [14]. 
GAPDH has also proven to be an attractive drug target in 
protozoa [15] such as trypanosomes [16] and Entamoeba 
[17], since many of these parasites rely solely on glycolysis 
for their energy supply. Structure- and catalytic mechanism-
based approaches have been applied to design compounds 
that inhibit the glycolytic enzymes of the parasites without 
affecting the corresponding proteins of the human host [18-
20]. For some trypanosomatid enzymes, potent and selective 
inhibitors have already been developed that affect only the 
growth of cultured trypanosomatids, and not mammalian 
cells [16]. 
  Towards the goal of discovering potent inhibitors for the 
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target for male contraceptive development, we carried out a 
high throughput screen (HTS) against purified recombinant 
human GAPDHS lacking the proline-rich region. An NAD-
dependent assay for GAPDHS activity was optimized and 
validated for HTS. We screened 56,000 compounds selected 
to maximize chemical diversity. From this collection, we 
identified 14 hits by dose-response confirmatory testing.  
MATERIALS AND METHODOLOGY 
Reagents 
  Unless otherwise stated all reagents were purchased from 
Thermo Fisher Scientific (Waltham, MA) or Sigma Aldrich 
(St. Louis, MO) at the highest level of purity possible.   
Human somatic GAPDH purified from erythrocytes (catalog 
# G6019) was purchased from Sigma Aldrich and was 
greater than 90% pure as judged by SDS-PAGE. DL-
glyceraldehyde 3-phosphate (GAP) (catalog # G5251) was 
purchased from Sigma-Aldrich. Costar 384-well, flat-
bottom, clear plates were from Corning (Lowell, MA) (cata-
log # 3702). The Prestwick Chemical Library was obtained 
from Prestwick Chemical (Washington, DC). The com-
pounds for high throughput screening and IC50 determina-
tions were obtained from Asinex Corporation (Moscow, 
Russia). 
Construction of the Recombinant Human GST-GAPDHS 
  Unless stated, all procedures were performed according 
to manufacturer’s procedures. The gene for human sperm-
specific gyceraldehyde-3-phosphate dehydrogenase 
(GAPDHS) (Accession No. NM_014364.4) lacking the 
proline-rich N-terminal region, and comprising residues 69-
408, was synthesized (GeneArt Inc., Burlington, CA) with 
optimal codon usage for bacterial expression. The GAPDHS 
gene was flanked by an EcoRI and a XhoI site that were used 
to sub-clone the gene into the prokaryotic GST fusion vector, 
pGEX-4T-1 (GE Healthcare Life Sciences, Piscataway, NJ). 
The predicted molecular weight of the GST-GAPDHS con-
struct was calculated as 63,729.39 Da. 
Expression and Purification of Hu GST-GAPDHS in E. 
coli 
  Expression of GST-GAPDHS was performed in the 
gapA-deficient E. coli strain DS112 [21] obtained from the 
E. coli Genetic Stock Center (New Haven, Connecticut) as 
strain CGSC#7563. For large scale expression and purifica-
tion, 6L cultures of DS112/GST-GAPDHS were grown at 
37
oC in M9 minimal media supplemented as described [21] 
and containing ampicillin and chloramphenicol. The cultures 
were grown at 37
oC to an OD ~0.5, the incubation tempera-
ture was reduced to 30
oC and the cell culture induced for 48 
h with a final concentration of 0.2 mM IPTG. Cells were 
harvested, resuspended in lysis buffer (DPBS, 1 mM PMSF 
(MP Biomedicals, Solon, OH), 1 mM EDTA (Promega, 
Madison, WI), 1 mM DTT (US Biochemicals, Santa Clara, 
CA), 10 g/ml lysozyme (Fisher BioReagents, Suwanee, 
GA), 0.1% Triton X-100) and lysed at 23,000 psi by passage 
through a M-110EH homogenizer (Microfluidics, Newton, 
MA). After centrifugation at 30,000g for 1 h, the resulting 
supernatant was added to pre-equilibrated Glutathione aga-
rose resin (Pierce, Rockford, IL) (6 ml resin/100 ml lysate) 
and incubated overnight at 4
oC. After washing, GST-
GAPDHS was eluted with 10 mM glutathione (Thermo Sci-
entific, Rockford, IL) in 50 mM Tris-HCl, pH 8.0. Purified 
GST-GAPDHS protein was stored at -80
oC. Recombinant 
GST-GAPDHS samples were analyzed by SDS-PAGE (4-
12% Bis-Tris gels, NuPAGE MOPS SDS running buffer, 
Invitrogen) and gels stained with Coomassie blue. Protein 
concentrations were estimated by Bradford assay (Bio-Rad 
Laboratories, Hercules, CA). Analytical size exclusion 
chromatography was carried out on a Superose 12 column 
(GE Healthcare) as previously described [22]. 
Enzymatic Assay for GAPDHS 
  The dehydrogenase activity of GAPDHS was measured 
kinetically by monitoring the accumulation of NADH at 340 
nm [23] immediately following the addition of the substrate, 
DL-glyceraldehyde-3-phosphate (GAP). One enzyme unit is 
defined as the amount of enzyme necessary for the formation 
of 1 mol of 1,3-diphosphoglycerate min
-1. GAPDH was 
assayed at pH 8.9, optimal for its activity [24]. For Km  
determination for GAP, the reaction mixture contained 
GAPDHS, 50 mM glycine, 50 mM potassium phosphate, pH 
8.9, 5 mM EDTA, 0.5 mM NAD and a 14 point GAP con-
centration range between 0 and 10 mM GAP. Assays were 
performed at room temperature. 
Compound Libraries and Handing 
  A chemical collection of 56,000 compounds was pur-
chased from Asinex Corp. All compounds in the Asinex li-
brary adhere to Lipinski’s rule of 5, with no more than 5 
hydrogen bond donors, no more than 10 hydrogen bond ac-
ceptors, a molecular weight under 500 g/mol, and a partition 
coefficient (LogP) less than 5 [25]. All compounds are regis-
tered in ActivityBase (IDBS Inc., Guildford UK) and can be 
positionally located in bar-coded 384-well plates with asso-
ciated SD file data. Compound handling for HTS was essen-
tially as previously described [26, 27]. Compounds are 
stored at 4
oC in 384-well Greiner V-bottom polypropylene 
plates (catalog # 781280) (Greiner Bio-One, Monroe, NC) in 
100% DMSO at 10 mM and 1 mM concentrations. For HTS, 
0.5 L of 1 mM compound in DMSO was spotted into col-
umns 3 - 22 of dry Costar clear flat bottom 384-well assay 
plates (catalog #3701, Corning Corp., Corning, NY) using a 
Biomek
® NX (Beckman Coulter Inc., Fullerton, CA) and 
P20 tips. Columns 1, 2, 23, and 24 were spotted with 0.5 L 
of DMSO for use as positive and negative controls. Dry 
spotting of compounds into assay plates was performed as a 
routine method to conserve compounds [26]. For dose-
response measurements, 4 L of the 10 mM DMSO stock of 
selected compounds was added to 1 L of DMSO using a 
Biomek
® NX. 
  The Prestwick collection containing 1,120 FDA approved 
compounds was prepared as 10 mM stocks in 100% DMSO. 
Compounds (0.5 L) were pre-spotted into the 384-well 
plates using a Biomek
® NX to give a final screening concen-
tration of 10 M.  
High Throughput Screening GAPDHS Assay 
  The high throughput screening (HTS) assay for 
GAPDHS is based on the standard spectrophotometric assay 
of GAPDH activity described above. For HTS, all steps were 
carried out at room temperature in Costar clear flat-bottom 
384-well plates pre-spotted with either 0.5 L DMSO or 0.5 
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tions carried out using a Thermo Multidrop 384-well liquid 
dispenser (Thermo Scientific, Waltham, MA). Reactions 
with inhibitors were carried out with a 15 min preincubation 
of compounds with 25 L of GAPDHS/NAD. The enzy-
matic reaction was then initiated by addition of 25 L of 
GAP substrate. The final HTS assay (50 L) contained 30 
nM GAPDHS, 50 mM glycine, 50 mM potassium phosphate, 
pH 8.9, 5 mM EDTA, 1 mM DTT, 1% DMSO, 0.5 mM 
NAD and 0.5 mM GAP and a final concentration of 10 M 
compound for single-point screening. For HTS, maximum 
signal positive controls contained only DMSO (no com-
pound), while the minimum controls were obtained by add-
ing all assay components except enzyme. Kinetic reads (at 
30 sec intervals for 5 min) of the plates were carried out on a 
Spectramax Plus 384 reader (Molecular Devices, Sunnyvale, 
CA). Inhibition data was analyzed in ActivityBase and using 
Microsoft Excel. Hits were defined using a standard devia-
tion based-hit threshold (signal mean () plus 3x the stan-
dard deviation () in the compound data, +3).  
Estimation of Assay Quality 
  The Z’-factor was used to assess the quality of the assay 
and estimate the screening window [28]. The Z’-factor in-
corporates both the dynamic range of the assay and well-to-
well variability. Values are obtained by running one whole 
384-well plate of maximum (max) signal control and one 
whole 384-well plate of minimum (min) signal control. Z’-
factor was calculated using the formula: Z’ = 1 - (3SDmax + 
3SDmin)/(Meanmax – Meanmin) 
where SD = standard deviation. Max = maximum signal. 
Min = minimum signal. 
Dose Response Measurements 
 For  IC50 determinations, serial dilutions of compounds (8 
mM stock concentration in DMSO) were performed in 100% 
DMSO with a two-fold dilution factor resulting in 10 final 
concentrations spanning 80 M to 0.165 M. The serially 
diluted compounds (0.5 L) were dry spotted into assay 
plates and were assembled as described for the single-
concentration screen. For each concentration, percent inhibi-
tion values were calculated and IC50 values and Hill slopes 
determined using a four-parameter dose-response (variable 
slope) equation in GraphPad Prism or using XLfit software 
(IDBS). Some compounds were also tested by dose response 
in the presence of detergent (0.01% Tween-20 final concen-
tration). In some cases, compounds were also tested by dose 
response against a form of human histag-GAPDHS ex-
pressed in the baculovirus/insect cell system [22]. Buffer 
conditions were as described above and his-GAPDHS was 
used at a final concentration of 60 nM in the assay. 
Ligand Efficiency Calculation 
 IC50 values were used to calculate ligand efficiency (LE 
or g) and binding efficiency index (BEI) [29]. Ligand effi-
ciency normalizes the binding energy of the ligand (G =  
-RTlnIC50) at 300 K (~27°C) to the number of non-hydrogen 
atoms in the molecule (g = G Nnon-H atoms
-1) [30], while 
BEI expresses binding affinity per total molecular weight 
(MW) of the inhibitor (BEI=-logIC50 MW
-1) [29].  
Compound Filter Assay 
  The ability of compounds to interfere with the GAPDHS 
assay readout was assessed as follows. The enzymatic assay 
was run kinetically as described above until an absorbance 
(A340) of 0.7 was reached. Compounds were then added to 
the reaction to a final compound concentration of 50 M and 
the A340 measured immediately after this addition. 
Statistical Analysis 
  GraphPad Prism 5 (GraphPad Software, San Diego, CA) 
was used for nonlinear regression statistical analysis. Graph-
Pad InStat Student’s two tailed t-test was used for comparing 
IC50 values, differences were considered significant at 
p<0.05. 
RESULTS 
  Expression of full-length GAPDHS in E. coli has proven 
difficult in quantities sufficient for screening a large number 
of compounds [7]. Substantially better yields and activities 
were obtained by elimination of the proline-rich N-terminal 
region [1] that is not required for enzyme activity [22]. 
When typical E. coli strains were used for expression, mass 
spectrometry analyses confirmed that mouse GAPDHS and 
the host bacterial GAPDH formed mixed tetramers, resulting 
in the co-purification of bacterial and recombinant enzymes 
(data not shown). A similar observation has been made for 
the rat GAPDHS expressed in E. coli with the purified 
tetrameric enzyme consisting of 3 subunits of E. coli 
GAPDH and 1 subunit of rat GAPDHS [7]. Our approach 
was to express recombinant human GAPDHS lacking the 
proline-rich N-terminal region in a GAPDH-deficient E. coli 
strain (CGSC strain #7563). Further, the form we expressed 
was a GST-GAPDHS fusion protein to improve solubility. 
The size and purity of soluble recombinant GST-GAPDHS 
was confirmed by SDS-PAGE with a band at ~ 60 kDa ob-
served (Fig. 1A). Typical yields were ~13 mg of purified 
GST-GAPDHS per 6L E. coli culture. Hu GST-GAPDHS 
protein purified from E. coli was further characterized by 
analytical size exclusion chromatography as previously de-
scribed [22]. GST-GAPDHS was applied to a Superose 12 
column and eluted as a mixture of three forms (Fig. 1B), 
with peak 1 eluting in the void volume. Comparison with 
known protein standards indicated that the elution volumes 
of peaks 2 and 3 corresponded most closely to the tetrameric 
and monomeric forms of GST-GAPDHS respectively, with 
~75% of the protein estimated as tetrameric, 10% mono-
meric and the remainder presumably in some aggregated 
form.  
  The GST-GAPDHS fusion protein had enzymatic activ-
ity, enabling us to avoid substantial losses that occurred dur-
ing thrombin cleavage to remove the GST protein tag. Con-
sequently, the uncleaved GST-GAPDHS protein was used 
for all subsequent studies and will be referred to as 
GAPDHS from here on. 
GAPDHS Assay Development and Optimization 
  GAPDHS activity was measured using a standard spec-
trophotometric assay monitoring the accumulation of NADH 
at 340 nm [23] following the addition of the substrate, DL-
glyceraldehyde-3-phosphate (GAP). The assay was devel-
oped with a final assay volume of 50 L in 384-well format. 
GAPDHS activity was measured kinetically by taking absor-
bance readings every 30 sec over 5 min. The GAPDHS ac-
tivity in the assay was directly proportional to the concentra-
tion of enzyme (Fig. 2). The Km values for GAP and NADDevelopment and Implementation of a High Throughput Screen  Current Chemical Genomics, 2011, Volume 5    33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Characterization of GST-GAPDHS. (A) SDS-PAGE analysis of purified recombinant human GST–GAPDHS. GST-GAPDHS was 
expressed in the gapA-deficient E. coli strain DS112 and purified using glutathione-Sepharose. Coomassie-Blue stained 4-12% Bis-Tris gel, 
lane M, Prestained protein markers (Novex); lane 1, recombinant human GST-GAPDHS (2 g). (B) Size exclusion chromatography of puri-
fied GST-GAPDHS. Purified human GST-GAPDHS was loaded on a Superose 12 column at 0.5 ml/min in 50 mM potassium phosphate pH 
7.0, 400 mM NaCl buffer. The molecular size of the peaks indicated by the numbers were estimated as described previously [22]. 
were determined as 1.1 mM (Fig. 3) and 0.1 mM (data not 
shown), respectively. Activity of the purified recombinant 
human GAPDHS was ~46 U/mg, comparable to the activi-
ties of commercial preparations of GAPDH purified from 
rabbit muscle (Sigma). For HTS, an assay concentration of 
30 nM GAPDHS was chosen which provided both an ade-
quate assay window and linear GAPDHS enzyme activity 
over the time of the assay. 
 
Fig. (2). GAPDHS Enzyme Titration. GAPDHS was titrated at the 
indicated concentrations under the final assay conditions. Data 
points represent average of four determinations per concentration. 
 
  For our preferred HTS scheme, 0.5 L of compound per 
well is pre-spotted in 384-well plates giving a final com-
pound concentration of 10 M in the final 50 L assay vol-
ume. Because the compounds to be screened are dissolved in 
DMSO, the DMSO tolerance of the assay was assessed. 
Concentrations up to 5% DMSO had no effect on GAPDHS 
activity (Fig. 4). For the HTS and dose response experi-
ments, the maximum concentration of DMSO is 1%. Addi-
tion of up to 1% BSA was also tested, but found to have no 
affect on GAPDHS activity in the assay (data not shown). 
Substrate concentrations were set at 0.5 mM NAD (5x Km 
NAD) and 0.5 mM GAP (0.5x GAP Km) with the goal of 
biasing the screen toward detection of GAP competitive 
compounds. 
 
Fig. (3). Determination of the Km value for GAP substrate. GAP 
was titrated at a 14 point concentration range between 0 and 10 mM 
in the assay using 8 nM GAPDHS. Km value was calculated using 
non-linear regression analysis for the Michaelis-Menten equation in 
GraphPad Prism 5. 
 
GAPDHS Assay Automation and Validation 
  To assess variability of the GAPDHS assay with full 
automation, triplicate 384-well DMSO plates in a typical 
“Min-Mid-Max” experiment [28, 31] were analyzed to de-
termine Z’-factor [28] as a measure of assay quality. To fa-
cilitate HTS, the assay was simplified into two steps using 
Multidrop 384 (Thermo Fisher) bulk dispensers (Table 1). 
The assay was run as a 5 min kinetic read. All plates were 
pre-spotted with 0.5 L DMSO using a Biomek NX liquid 
handling workstation. Initial experiments were conducted in 
the absence of compounds to evaluate the robustness of the 
assay window by measuring statistically significant changes 
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0.5x GAPDHS concentration (mid signal ) and 1x 
GAPDHS concentration (maximum signal ) (Fig. 5A).  
 
Fig. (4). Tolerance of GAPDHS assay to DMSO. DMSO was tested 
in the GAPDHS HTS assay (30 nM GAPDHS, 50 mM glycine, 50 
mM potassium phosphate, pH 8.9, 5 mM EDTA, 1 mM DTT, 1% 
DMSO, 0.5 mM NAD and 0.5 mM GAP) at the indicated concen-
trations of DMSO. 
 
  The data yielded a calculated Z’-factor for individual 
plates of 0.88 and CVs <5% (Fig. 5B) demonstrating a suit-
able assay window and acceptable variability for HTS as 
typically defined [28, 31, 32] and [NIH Chemical Genomics 
Center Assay Guidance Manual: (http://spotlite.nih.gov/ as-
say/index.php/Table_of_Contents)]. For HTS, typically 10-
20 compound plates are screened in one run. To assess the 
stability of the assay over such a ten 384-well plate run, a 
variability study was performed allowing compound pre-
incubation with GAPDHS and NAD for 15 min or 60 min to 
simulate the first and tenth plate conditions, respectively. In 
comparison, the data yielded a calculated Z’ for individual 
plates of 0.83 and CVs of 5.03% for the 60 min preincuba-
tion study demonstrating the robustness of the assay over the 
time frame required to screen ten 384-well plates. The assay 
was repeated for a second day with comparable results for Z’ 
and CVs (data not shown). The scheme used for HTS was to 
add the GAPDHS/NAD solution to the 10 plates at 6 min 
intervals, to add GAP to each plate after its 15 min com-
pound incubation, and then to read immediately thus ensur-
ing that compound incubation times were identical for all 
wells on all plates (Table 1). 
GAPDHS Pilot Screen 
  As a final validation, a small test set of diverse com-
pounds was screened to determine the performance of the 
GAPDHS assay under HTS conditions in the presence of 
typical small molecule compounds. In this pilot screen, the 
process and the plates with controls were set-up exactly as 
for the primary screen. We used the Prestwick collection, a 
purchased compound library made up of 1,120 compounds 
with established biological activities, 90% of which are 
FDA-approved drugs. The Prestwick library was screened at 
10 M in the automated GAPDHS assay and hits were iden-
tified using a standard deviation based hit-threshold [33] 
(signal mean () plus 3x the standard deviation () in the 
compound data, +3). The Z’-factors for the controls on 
each of the four plates were all >0.75. From single-point 
screening of the Prestwick collection, four compounds had 
percent inhibition values above the 30% threshold (Fig. 6A). 
The compound distribution data scatter as shown in the his-
togram (Fig. 6B) and box plot (Fig. 6C) shows a normal (un-
skewed) distribution with a mean set to zero. Two of the four 
compounds confirmed with dose response in this assay (Ta-
ble 2), including propidium iodide with an IC50 value of 28 
M (Fig. 6D), yielding an overall hit-rate of 0.2%. 
 
Fig. (5). GAPDHS assay variability assessment. (A) 384-well plates were pre-spotted with 0.5 L of DMSO using a Biomek NX. One plate 
each was used to determine the maximum signal (), mid signal () and minimum signal (). The Min, Mid and Max plates contained final 
assay concentrations of 0, 16 and 32 nM GAPDHS respectively. After 15 min of pre-incubation, GAP was added and rates determined over 5 
min with 30 sec reads. The data represent values measured in individual wells, consisting of 320 replicates for each condition. (B) The vari-
ability for inhibition was determined from the max and min plates. Z’-factors, standard deviations (SD) and coefficient of variance (CV) 
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Table 1.  Automation Protocol for GAPDHS HTS Assay 
Step Event  Parameter  Description 
1 Pre-spot  0.5  L  Add DMSO/test compound to 384-well plates using Biomek NX 
2 Dispense  25  L  Add GAPDHS and NAD solution to a set of ten plates using Multidrop 384 
3  Incubate  15 min  Room temperature 
4 Dispense  25  L  Add GAP substrate to one plate using Multidrop 384 
5 Read  A340  SpectraMax plate reader; 
5 min kinetic read  
6 Dispense  25  L  Repeat steps 4 and 5 for remaining nine plates 
 
 
Fig. (6). Pilot screening results from the Prestwick FDA-approved drug library. (A) Pilot screen scatter for the 1,120 compound Prestwick 
library. Each point represents the percent inhibition value for a single compound. Each 384-well plate is represented by a different color. The 
threshold for defining actives is set at +3. (B) Histogram of screening data showing a normal distribution. (C) Box plot representing quarti-
les and outliers. (D) Dose response confirmation for active compound PWK-433663 (propidium iodide) showing a 28 M IC50 value (average 
of three independent determinations). 
GAPDHS HTS and Inhibitor Identification 
  To identify inhibitors of human GAPDHS, a diverse col-
lection of 28,880 small organic molecules selected from the 
purchased Asinex set was screened in 384-well format (90 
plates) at 10 M single point concentration. Actives were 
identified using a standard deviation based-hit threshold 
(+3). GAPDHS percent inhibition values were plotted for 
each compound (Fig. 7A). The compound distribution data 
scatter as shown in the histogram (Fig. 7B) and box plot 
(Fig. 7C) shows a normal (un-skewed) distribution and a 
standard deviation in compound data of 8.8%. The average 
Z for this screen was 0.88. Thirty one active compounds 
exhibiting GAPDHS inhibition values above the 30% 
threshold were identified (Fig. 7A) for a primary hit rate of 
0.1%. 
 Dose  response/IC50 determinations were conducted for 
compounds identified as single-point actives. Data from 
these assays were analyzed in ActivityBase and plots were 
assessed for IC50 and Hill slope values. Of the 31 compounds 
tested in dose response, nine compounds exhibited sigmoidal 
dose response behavior and were confirmed as hits with IC50 
values ranging from 1.8 to 42.5 M for an overall confirma-
tion rate of 29% (Table 3). Inhibition by three other com-
pounds (12-14 in Table 3) was trending upwards at the high-
est doses tested. A second round of screening of the remain-
ing Asinex collection yielded two more hits after confirma-
tion (10 and 11 in Table 3). For all fourteen hits, the percent 
inhibition values from the primary screen, IC50 values and 
Hill slope values are shown in Table 3. The dose-response 
curve for the most potent GAPDHS inhibitor identified from 
the diversity screen, (compound 3), is shown in Fig. (8) and 
exhibits an IC50 value of 1.8 M and a Hill slope of 1.1.  36    Current Chemical Genomics, 2011, Volume 5  Sexton et al. 
Table 2.  Inhibitors of Human GAPDHS Identified from a Pilot Screen of the Prestwick Set 
No.  Compound ID
a  Name Structure 
% Inhibition in 
HTS 
IC50 (M)
b 
Hill Slope 
Value
c 
1 PWK-433663 Propidium  iodide 
N+ N+
I-
I-
NH2
H2N
 
69.2 28  1.01 
2 PWK-433331  Menadione 
O
O  
37.9 
40% inhibition 
at 80 M 
1.10 
aPrestwick chemical identifier number. 
bFor IC50 determinations, serial dilutions of compounds were tested starting at a high concentration of 80 M. If 50% inhibition was not achieved at top dose, value is shown as % 
inhibition at 80 M. 
cIC50 and Hill slope values determined by XLfit software (ID Business Solutions).  
 
 
Fig. (7). High throughput screening of human GAPDHS. Compounds were pre-spotted (0.5 l) into 384-well plates and the human GAPDHS 
enzyme assay carried out in a final volume of 50 l as described in the materials and methodology. (A) Scatterplot showing percent inhibition 
values for compounds screened and with actives shown as diamonds above a 3 sigma threshold. Positive controls are shown in green, nega-
tive controls in blue and Asinex compounds in black. (B) Histogram of screening data showing a normal distribution and, (C) Box plot repre-
senting quartiles and outliers. 
  To assess hits based on both potency and molecular 
weight, values were calculated for ligand efficiency (LE) and 
binding efficiency index (BEI) (Table 3). These parameters 
allow inhibitor activities to be compared independent of pos-
sible molecular weight biases [29, 30]. Based on IC50 values, 
compounds 2 and 3 were the most inhibitory (6.5 and 1.8 
M, respectively, Table 3). These compounds have a rela-
tively low molecular weight (216 and 207 Da, respectively) 
and maintained their potent inhibitory ranking after using LE 
and BEI equations to normalize inhibitory activity to mo-
lecular weight among the compounds identified in our 
screen. An order of magnitude higher IC50 (16.8 M) was 
observed for compound 4 (170 Da), though the relative po-
tency of this inhibitor increased significantly after normali-
zation. Of the inhibitors yielding a dose-response curve, 
compounds 6 and 7 (among the highest MW in the set) had 
the weakest LE and BEI rating, while their IC50 values were 
mid-range. LE values varied from 0.21 to 0.55 kcal mol
-1 
non-H atom
-1; while BEI ranged from 11 to 28. In general, 
comparable LE and BEI values were obtained. In both cases 
higher numbers correspond to increased efficiency.  
  Compounds eliciting dose-response curves using the 
GST-GAPDHS were also tested against the his-GAPDHS 
form of the enzyme that we have recently produced using the 
baculovirus/insect cell system [22]. All of the compounds 
tested had comparable IC50 values on both GAPDHS en-
zymes (Table 3). 
  To assess selectivity of the GAPDHS hits versus the so-
matic form of GAPDH, the GAPDHS hits were tested for 
dose-response in a comparable assay using commercially 
available somatic GAPDH purified from human erythrocytes 
(Sigma). The assay for human GAPDH was first validated Development and Implementation of a High Throughput Screen  Current Chemical Genomics, 2011, Volume 5    37 
Table 3.  Activities of Confirmed Hits from Chemical Library Screen of Recombinant Human GAPDHS 
GST-GAPDHS  
No.  % Inhibition in 
HTS 
IC50 (M)
a 
Hill Slope 
Value
b 
LE
c 
(kcal mol
-1 non-H atom
-1) 
BEI
d 
His-GAPDHS  
IC50 (M)
f 
1 70.1%  10.7  1.7  0.30  17  13 
2 102.5%  6.5  1.1  0.47  24  11 
3 90.3%  1.8  1.1  0.53  28  3 
4 64.2%  16.8  1.0  0.55  28  30 
5 56.0%  8.3  1.4  0.32  16  10 
6 103.4%  11.9  1.0  0.27  14  12 
7 45.9%  20.8  0.9  0.21  11  22 
8 103.5%  36.1  1.1  0.38  20  44 
9 33.8%  42.5  1.8  0.40  18  26 
10 51.3% 
45% inhibition at 80 
M 
0.6 N/A
e N/A  ND 
11 101.1%  11.0  1.4  0.36  18  13 
12 86.9% 
30% inhibition at 80 
M 
N/A N/A  N/A  ND 
13 52.6% 
30% inhibition at 80 
M 
N/A N/A  N/A  ND 
14 102.0% 
30% inhibition at 80 
M 
N/A N/A  N/A  ND 
aFor IC50 determinations, serial dilutions of compounds were tested starting at a high concentration of 80 M versus the E. coli expressed GST-GAPDHS. If 50% inhibition was not 
achieved at top dose, value is shown as % inhibition at 80 M. IC50 values are the average for at least three independent determinations. 
bIC50 and Hill slope values determined by XLfit software (ID Business Solutions). 
cLE: ligand efficiency (g=G Nnon-H atoms
-1), a measure of the binding energy of the ligand per non-hydrogen atom [30]. 
dBEI: binding efficiency index (BEI=-logIC50 MW
-1) a measure of the binding affinity of the ligand per ligand molecular weight [29]. 
eN/A not applicable, as a dose response curve was not generated. 
fIC50 determinations from dose response against the baculovirus expressed his-GAPDHS [22]. Values determined by XLfit software (ID Business Solutions). ND, not determined. 
 
 
 
 
 
 
 
 
 
Fig. (8). IC50 value determination for compound 3. Compound 3 
was serially diluted in DMSO and the dose response assay carried 
out as detailed in materials and methodology and then transferred 
to assay plates for the GAPDHS enzyme assay. The 1.8 M IC50 
value for compound 3 was calculated from the average of three 
independent determinations. 
 
(data not shown) using procedures previously described for 
the GAPDHS assay. For a subset of compounds, the corre-
sponding IC50 values versus the somatic GAPDH along with 
compound structures are shown in Table 4. For compounds 8 
and 9 we observed no statistically significant differences 
between the IC50 values for sperm GAPDHS versus somatic 
GAPDH. Because the remaining compounds in Table 4 did 
not yield complete dose response curves we could not con-
clude whether there were any statistical differences between 
the two isozymes. 
  K-means clustering was performed to group compounds 
by similarity with a 0.65 cutoff. Two of the 14 compounds 
(compounds 13 and 14) that showed some inhibition of 
GAPDHS were of the same scaffold. The remaining 12 
compounds were structurally unrelated.  
Follow Up Assays 
  To further confirm GAPDHS hits and eliminate false 
positives, a series of follow up assays were carried out. Two 
of the confirmed compounds (displaying full dose response) 
from Table 3 (compounds 4 and 6) were repurchased from 
Asinex as dry powders to test in follow up assays. Using dry 
powder, compound 6 (Table 3) had an IC50 value of 13 M 
(Fig. 9) very close to that observed (11 M) from dose re-
sponse using master plate derived compound (Table 3). Fur-
ther, this compound had a comparable IC50 value of 17 M 38    Current Chemical Genomics, 2011, Volume 5  Sexton et al. 
Table 4.  Recombinant GAPDHS Activity Versus Somatic GAPDH and Structures for a Subset of GAPDHS Hits 
Compound No.  Structure  GAPDHS IC50 (M)
a  Somatic GAPDH IC50 (M) 
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30% inhibition at 80 M  <30% inhibition at 80 M 
13 

30% inhibition at 80 M  <30% inhibition at 80 M 
14 
  N
N
N
N
Cl

30% inhibition at 80 M  <30% inhibition at 80 M 
aFor IC50 determinations, serial dilutions of compounds were tested starting at a high concentration of 80 M. If 50% inhibition was not achieved at top dose, value is shown as % 
inhibition at 80 M.
 IC50 values determined by XLfit software (ID Business Solutions). 
 
Fig. (9). IC50 value determinations for compound 6 in the presence 
and absence of detergent. Compound 6 was serially diluted in 
DMSO and the GAPDHS enzymatic assay carried out in the ab-
sence or presence of 0.01% Tween-20.  
when tested in the presence of 0.01% Tween-20 (Fig. 9). 
Menadione, identified from the pilot screen of the Prestwick 
set (Table 2), also displayed comparable IC50 values of 47 
M and 53 M respectively when tested in the absence and 
presence of 0.01% Tween-20. 
  These compounds were also assessed for their ability to 
interfere with the GAPDHS enzymatic assay. The GAPDHS 
assay was first run kinetically in the absence of any com-
pound until an A340 of ~0.7 was reached. Compounds were 
then added to a final concentration of 50 M and the A340 
read again immediately after compound addition. The result-
ing A340 values for the GAPDHS assay with menadione, 
compound 4 and compound 6 were essentially unchanged at 
0.78, 0.67 and 0.69, respectively, suggesting that these com-
pounds do not quench the NADH signal. 
DISCUSSION 
  GAPDHS is expressed only in male germ cells and is 
required for sperm motility and male fertility [10]. It is an 
essential enzyme in the central metabolic pathway of glyco-
lysis and is the only GAPDH isozyme in sperm. Conse-Development and Implementation of a High Throughput Screen  Current Chemical Genomics, 2011, Volume 5    39 
quently, GAPDHS has been proposed as an excellent contra-
ceptive target, particularly if this isozyme can be selectively 
inhibited without blocking the somatic GAPDH enzyme 
found in all other tissues. We were able to produce human 
GAPDHS by expression of a GST-GAPDHS fusion protein 
in an E. coli strain lacking endogenous GAPDH, and the 
availability of this enzyme provides an excellent basis for the 
identification of compounds that inhibit the activity of hu-
man GAPDHS. The GST-GAPDHS was pure as judged by 
SDS-PAGE and existed predominantly as a tetramer as as-
sessed by analytical size exclusion chromatography. It is 
unclear why some of the GST-GAPDHS eluted in the void 
volume, although this may be due to the solubility of the 
enzyme when produced in E. coli or due to increased enzyme 
association due to the GST tag. Although some of the GST-
GAPDHS protein eluted at the void and is presumably ag-
gregated, this GST-GAPDHS enzyme preparation had a 
higher specific activity (46 U/mg) than the his-GAPDHS 
form (28 U/mg) that we have recently expressed in the bacu-
lovirus/insect cell expression system [22]. 
  We first adapted and validated an HTS assay in 384-well 
format based on a standard GAPDH spectrophotometric as-
say [23] to measure inhibition of recombinant human 
GAPDHS activity. The assay signal was demonstrated to be 
proportional to GAPDHS enzyme concentration and up to 
5% DMSO was tolerated in the assay. As assessed by whole 
384-well plate min-max variability experiments, the assay 
was robust with Z’ values >0.8 and the assay window was 
stable for 60 minutes allowing ten plates to be run in a single 
batch. Alpha-chlorohydrin has been reported as a GAPDHS 
inhibitor (reviewed in [11]), with its metabolite S-3-
chlorolactaldehyde being the actual inhibitory form [34, 35]. 
Our attempts to generate S-3-chlorolactaldehyde and test it 
as an inhibitor of GAPDHS are ongoing. In the absence of a 
GAPDH control inhibitor, a no enzyme addition was used as 
the minimum control with the expectation that the Z’ would 
be higher relative to using a known inhibitor for the mini-
mum control.  
  We and others have determined that a test screen of a 
diverse set of compounds such as the Prestwick set has great 
value in evaluating an assay’s response to compounds with 
varied structures (rather than evaluating with just DMSO) 
under HTS conditions [31]. The value of the Prestwick col-
lection is that it may also yield interesting inhibitory com-
pounds that already have a wealth of associated data [36, 
37]. Screening of the 1,120 compound Prestwick collection 
against recombinant human GAPDHS, yielded two con-
firmed inhibitors, propidium iodide and menadione. One of 
these compounds, menadione, was previously identified as a 
non-selective inhibitor of GAPDH isozymes in vivo (PMID: 
12788228, PMID: 2353814). To our knowledge, no reports 
of propidium iodide inhibiting GAPDH enzymes have been 
published. Both menadione and propidium iodide were also 
identified as actives [22] when we subsequently screened the 
Prestwick collection against the purified his-GAPDHS ex-
pressed in the baculovirus/insect cell system. 
  We used the validated GAPDHS high throughput assay 
to screen a diverse library of small molecules to identify in-
hibitors of GAPDHS activity. From the screen, confirmed 
inhibitors of GST-GAPDHS had IC50 values ranging from 
1.8 to 42.5 M. As an additional confirmation, we also tested 
those compounds eliciting dose-response curves versus the 
his-GAPDHS form of the enzyme that we have recently pro-
duced using the baculovirus/insect cell system [22] and 
comparable IC50 values were obtained on both forms of 
GAPDHS.  
  Hits identified during the high-throughput screen varied 
in potency. This variation may correlate directly to ligand 
molecular weight. Two related equations have been intro-
duced to normalize potency to molecular weight to improve 
comparisons of ligand activity. Ligand efficiency (LE) nor-
malizes binding energy to the number of non-hydrogen at-
oms in the ligand [30], whereas the binding efficiency index 
(BEI) normalizes binding affinity to ligand molecular weight 
[29]. The latter index was introduced to account for large 
MW differences apparent among diverse heteroatoms [29]. 
We used both equations to divorce ligand inhibitory activity 
from a possible MW bias in our data. In general, the differ-
ent equations yielded comparable results (Table 3). Ranking 
compound activity by IC50 or LE/BEI would result in asym-
metric lists, suggesting molecular weight affects the ob-
served IC50 values. While the relative ranking of some in-
hibitors improved upon normalization (notably compound 
4), the most potent and relatively low molecular weight 
compounds (compounds 2 and 3) remained at the top of both 
lists, suggesting at least three promising GAPDHS inhibitory 
hits have been identified in this study. 
  A critical phase of hit confirmation is to distinguish those 
compounds that are targeting the enzymatic activity from 
those that might be acting as false positives [32]. Dose re-
sponse behavior was used to confirm hits identified during 
HTS. The confirmation rate of 29% suggested that a number 
of false positives may have been eliminated during dose re-
sponse testing. False positives may act by interfering with 
assay read-out, chemically modifying the enzyme or by ag-
gregation-based affects [38]. Compounds with dose-response 
curves were further analyzed using Hill slope values. Those 
with high Hill slopes (>2) would typically be eliminated to 
avoid compounds that may act as aggregators or covalent-
modifiers [38]. The majority of confirmed GAPDHS inhibi-
tors had Hill slope values between 0.9 and 1.1, with none 
having values >2. However, at this stage we did not elimi-
nate any hits based solely on Hill slope value, since com-
pounds acting allosterically or irreversibly may also have 
interest as potential leads as GAPDHS inhibitors. Another 
mechanism of artifactual inhibition is compound aggregation 
followed by interaction with the enzyme [38-40]. This inhi-
bition can be distinguished by its detergent sensitivity and a 
counter-screen using low concentrations of detergent was 
able to discriminate between classical 1:1 inhibitors and 
promiscuous aggregators [38, 39]. We used a concentration 
of Tween-20 (0.01%) at the higher end of the range of sug-
gested detergent concentrations [39], to assess whether inhi-
bition profiles were detergent-sensitive or detergent-
resistant. We found that inclusion of Tween-20 had no effect 
on the inhibition profile of compound 6, indicating that it is a 
standard 1:1 reversible inhibitor. Assays based on measuring 
absorbance are also susceptible to compound-dependent in-
terference [31, 32]. This was minimized in part by running 
our assay in kinetic mode. In addition, to assess compound 
interference, we used a filter assay in which compound is 
added after completion of the enzymatic reaction and the 
absorbance immediately read. For those compounds that we 40    Current Chemical Genomics, 2011, Volume 5  Sexton et al. 
tested from dry powder (compounds 4, 6, 10, 11, 12 and me-
nadione), we did not observe any compound-dependent 
quenching of the NADH signal.  
  All the compounds identified as confirmed hits in Table 3 
will be either re-sourced as dry powders or resynthesized for 
further confirmation and biological testing. Unfortunately, 
the most active compound (compound 3, Table 3) is unavail-
able through any commercial supplier so we are currently 
planning to synthesize it. Compounds will be tested in coun-
terscreens decribed herein to assess detergent sensitivity and 
assay interference. Isothermal calorimetry will also be used 
to measure the stoichometry of binding. Confirmed hits will 
then be tested for their ability to inhibit sperm function, in-
cluding effects on quantitative parameters of sperm motility 
determined by computer-assisted sperm analysis (CASA) 
and CASAnova, a recently developed support vector ma-
chines model [41]. 
  A number of approaches will be taken to identify addi-
tional GAPDHS inhibitors, including substructure searches 
to identify similar compounds from our in house library and 
external libraries, and using structure-based drug design 
which has already proved successful for targeting GAPDH in 
parasites [15, 18-20]. Structures for human GAPDHS are 
available in the pdb database (3PFW and 3H9E) and will be 
used for assessing both our current hits and for structure-
based drug design approaches. Alternative assay formats 
may also be utilized for additional screens including coupled 
assays for GAPDHS [42] and those using the resazu-
rin/diaphorase system [43]. 
   Structures and selectivity data for those compounds not 
included in Table 4 were not disclosed for intellectual prop-
erty considerations. Additional studies using purchased 
powders are underway to further evaluate these compounds 
and identify others that inhibit GAPDHS, focusing on those 
that exhibit the highest potency and selectivity for the sperm 
isozyme. Those GAPDHS inhibitors showing little selectiv-
ity versus the somatic form may still have utility as molecu-
lar probes to assess the role of GAPDHS in sperm function. 
Details on the mechanism of action, structure-activity rela-
tionships, selectivity, and activity in sperm assays of the 
most potent GAPDHS inhibitors will be detailed in a forth-
coming manuscript.  
CONCLUSION 
  A high throughput assay for sperm-specific glyceralde-
hyde-3-phosphate dehydrogenase (GAPDHS) was optimized 
and validated for the identification of small molecule inhibi-
tors. The robustness of the GAPDHS primary assay was con-
firmed by whole plate variability studies. Screening of a 
small molecule diversity library identified a number of in-
hibitors of recombinant human GAPDHS with IC50 values 
ranging from 1.8 to 42 M. These compounds may provide 
useful scaffolds as molecular tools to probe the role of 
GAPDHS in sperm function or for developing potent and 
selective GAPDHS inhibitors leading to novel contraceptive 
agents.  
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